Welcome to our dedicated page for Exelixis news (Ticker: EXEL), a resource for investors and traders seeking the latest updates and insights on Exelixis stock.
Exelixis Inc (EXEL) is a leading biopharmaceutical company focused on developing innovative cancer therapies through cutting-edge small molecule research. This page serves as a comprehensive resource for all official company updates and oncology-related developments.
Access timely EXEL news including FDA approvals, clinical trial results, and strategic partnerships with global pharmaceutical leaders. Investors will find essential updates on earnings reports, research milestones, and therapy commercialization efforts that demonstrate the company's progress in oncology treatment innovation.
Our curated news collection provides verified information about EXEL's drug development pipeline, regulatory achievements, and collaborative research initiatives. The content is maintained to support informed analysis of the company's market position and scientific advancements in cancer care.
Bookmark this page for direct access to Exelixis' latest press releases and objective reporting on their contributions to targeted cancer therapies. Check regularly for updates reflecting the company's ongoing work in transforming oncology treatment paradigms.
The nivolumab combination showed a 63% objective response rate and 90% disease control rate. At median follow-up of 20.1 months, the 12-month duration of response was 73.4%, with median progression-free survival of 18.5 months.
The nivolumab-relatlimab combination demonstrated a 40% objective response rate and 90% disease control rate. At 15.9 months follow-up, the 12-month duration of response was 74.1%, with median progression-free survival of 13.0 months.
While treatment-emergent adverse events occurred in all patients, the safety profile was manageable. The 100mg dose of zanzalintinib was selected for ongoing expansion cohorts based on preliminary results.
Exelixis (NASDAQ: EXEL) has announced its participation in three upcoming investor conferences in May and June 2025. The company will participate in fireside chats at the TD Cowen 6th Annual Oncology Innovation Summit (May 27), the William Blair 45th Annual Growth Stock Conference (June 3), and the Jefferies Global Healthcare Conference 2025 (June 4).
All presentations will be accessible via webcast on www.exelixis.com under the Investors & News section's Event Calendar page. Replay recordings will remain available for at least 30 days after the events.
Exelixis (NASDAQ: EXEL) has initiated the dose-escalation stage of a Phase 1 clinical trial for XB628, a first-in-class bispecific antibody, in patients with recurrent advanced or metastatic solid tumors. The drug candidate was developed in collaboration with Invenra Inc., targeting NK group 2 member A (NKG2A) and programmed cell death-ligand 1 (PD-L1). XB628 functions as a natural killer (NK) cell engager, representing a novel approach in cancer immunotherapy.
Exelixis (NASDAQ: EXEL) has announced its participation in two major investor conferences in May 2025. The company will be featured in fireside chats at the BofA Securities 2025 Health Care Conference in Las Vegas on May 14 at 1:40 p.m. ET, and at the RBC Capital Markets 2025 Global Healthcare Conference in New York City on May 20 at 10:30 a.m. ET.
Interested parties can access the webcasts through the Event Calendar page on www.exelixis.com under the Investors & News section. Replay recordings will remain available on the website for a minimum of 30 days after the events.
Exelixis (Nasdaq: EXEL) has scheduled the release of its first quarter 2025 financial results for Tuesday, May 13, 2025, after market close. The company will hold a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results and provide a business update.
Interested participants can access the event through:
- Conference call: Registration required via provided link for dial-in number and unique PIN
- Live webcast: Available on www.exelixis.com under Investors & News section's Event Calendar page
- Replay: Will be archived on the company website for one year
Exelixis (NASDAQ: EXEL) has received FDA approval for CABOMETYX® (cabozantinib) to treat previously treated advanced neuroendocrine tumors (NET). The approval covers two specific indications: advanced pancreatic NET (pNET) and extra-pancreatic NET (epNET) in adults and pediatric patients 12 years and older.
The approval is based on the phase 3 CABINET trial results, which showed significant improvement in progression-free survival compared to placebo. CABOMETYX becomes the first and only FDA-approved systemic treatment for previously treated NET, regardless of primary tumor site, grade, somatostatin receptor expression, and functional status.
The National Comprehensive Cancer Network has updated its guidelines to include cabozantinib as a category 1 preferred regimen for well-differentiated advanced NET and category 2A for other forms. The safety profile was consistent with previous findings, though higher hypertension incidence was noted compared to other tumor types.
Exelixis (NASDAQ: EXEL) will present preclinical data for four pipeline molecules at the AACR Annual Meeting 2025 in Chicago. The presentations will showcase both small molecule and biotherapeutic development candidates for advanced solid tumors.
The pipeline includes:
- XL495: A PKMYT1 inhibitor showing potential anti-tumor activity, currently in phase 1 clinical trials
- XB371: A tissue factor-targeting antibody-drug conjugate with planned FDA application in 2025
- XL309: A USP1 inhibitor active in BRCA 1/2 mutations, currently in phase 1 trials
- XB628: A first-in-class PD-L1 x NKG2A bispecific antibody with FDA-cleared IND application
FAQ
What is the current stock price of Exelixis (EXEL)?
What is the market cap of Exelixis (EXEL)?
